Cargando…
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing–remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182701/ https://www.ncbi.nlm.nih.gov/pubmed/29525836 http://dx.doi.org/10.1007/s00415-018-8822-y |